Clinical Trial Update: FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a FAD subtype-guided combination therapy in unresectable hepatocellular carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING